A case of guselkumab‐induced alopecia areata

Australasian Journal of DermatologyVolume 64, Issue 3 p. e297-e298 CLINICAL LETTER A case of guselkumab-induced alopecia areata Nilgün Şentürk MD, Nilgün Şentürk MD Department of Dermatology, Ondokuz Mayıs University Faculty of Medicine, Samsun, TurkeySearch for more papers by this authorRamazan Çetin MD, Corresponding Author Ramazan Çetin MD [email protected] orcid.org/0000-0001-9200-222X Department of Dermatology, Ondokuz Mayıs University Faculty of Medicine, Samsun, Turkey Correspondence Ramazan Çetin, Department of Dermatology, Ondokuz Mayıs University Faculty of Medicine, Korfez, 55280 Atakum, Samsun, Turkey. Email: [email protected]Search for more papers by this author Nilgün Şentürk MD, Nilgün Şentürk MD Department of Dermatology, Ondokuz Mayıs University Faculty of Medicine, Samsun, TurkeySearch for more papers by this authorRamazan Çetin MD, Corresponding Author Ramazan Çetin MD [email protected] orcid.org/0000-0001-9200-222X Department of Dermatology, Ondokuz Mayıs University Faculty of Medicine, Samsun, Turkey Correspondence Ramazan Çetin, Department of Dermatology, Ondokuz Mayıs University Faculty of Medicine, Korfez, 55280 Atakum, Samsun, Turkey. Email: [email protected]Search for more papers by this author First published: 25 April 2023 https://doi.org/10.1111/ajd.14062Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Chiricozzi A, Costanzo A, Fargnoli MC, Malagoli P, Piaserico S, Amerio P, et al. Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis. Eur J Dermatol. 2021; 31(1): 3–16. 10.1684/ejd.2021.3965 PubMedWeb of Science®Google Scholar 2Eldirany SA, Myung P, Bunick CG. Ixekizumab-induced alopecia areata. JAAD Case Rep. 2019; 6(1): 51–3. 10.1016/j.jdcr.2019.10.012 PubMedGoogle Scholar 3Guttman-Yassky E, Nia JK, Hashim PW, Mansouri Y, Alia E, Taliercio M, et al. Efficacy and safety of secukinumab treatment in adults with extensive alopecia areata. Arch Dermatol Res. 2018; 310: 607–14. 10.1007/s00403-018-1853-5 CASPubMedWeb of Science®Google Scholar 4Garcovich S, De Simone C, Genovese G, Berti E, Cugno M, Marzano AV. Paradoxical skin reactions to biologics in patients with rheumatologic disorders. Front Pharmacol. 2019; 10:282. 10.3389/fphar.2019.00282 CASPubMedWeb of Science®Google Scholar 5Macklis P, Porter C, Feldman S. A case of late-onset alopecia areata. J Drugs Dermatol. 2022; 21(4): 420–1. PubMedWeb of Science®Google Scholar Volume64, Issue3August 2023Pages e297-e298 ReferencesRelatedInformation